PharmaCyte Biotech’s Pancreatic Cancer Therapy Passes Critical FDA-Required Tests as Countdown to IND Submission Begins


NEW YORK, NY, Jan. 27, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) announced that its clinical trial product, which will be employed during the company’s upcoming Phase 2b clinical trial to treat locally advanced, inoperable pancreatic cancer (LAPC), has passed each of the U.S. Food and Drug Administration’s (FDA) required “release tests” for safety and functionality.  With a clinical trial product that has proven to be safe and functional, PharmaCyte is now “on-the-clock” for its submission of an Investigational New Drug application or “IND” package to the U.S. FDA requesting a Phase 2b clinical trial in LAPC at trial sites throughout the United States.

In a series of 10 “release tests” over two batches of the company’s clinical trial product for a total of 20 “release tests,” PharmaCyte’s signature live-cell encapsulation technology, Cell-in-a-Box®, performed admirably and proved to be both safe to place into humans in a clinical trial, and to function properly.  During the tests, the more than 20,000 genetically modified live cells that fully fill each Cell-in-a-Box® capsule were functioning as expected after being manufactured, placed into syringes, frozen, thawed and then tested for enzymatic activity, cell viability, and biologic activity among a host of other tests.

And now that “release testing” has ended successfully, Austrianova will issue 2 Certificates of Analysis to PharmaCyte—1 for each manufactured and tested batch of the company’s clinical trial product.  Additionally, Austrianova will turn over all of the completed batch records to PharmaCyte from both production runs and the subsequent “release testing.”  The data generated from these tests are necessary information that must be entered into the company’s IND application. 

PharmaCyte has methodically taken extra steps to position the company for a greater chance at success once the IND is submitted to the FDA.  One such step is the manufacture and testing of two batches of its clinical trial product, which was requested by cGMP Validation, the company taking responsibility for releasing the clinical trial product into the U.S. for use in PharmaCyte’s upcoming clinical trial.

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, commenting on manufacturing a second batch of the company’s clinical trial product, said, “Our GMP consultant, cGMP Validation, has informed us that while two successful manufacturing runs are not required by the FDA to request a Phase 2b clinical trial, it could go a long way in demonstrating to the FDA that our manufacturing process is robust and reproducible – manufacturing qualities that are highly embraced by the FDA.”

Successfully completing the manufacturing process of PharmaCyte’s clinical trial product, conducting and successfully completing “release testing” on both batches of the company’s product, and the data being generated from those tests are all critical to the completion of PharmaCyte’s IND package.  With the announced success of the “release tests,” PharmaCyte has essentially conquered what was the greatest hinderance in the company’s ability to move forward with completing its IND application.

Because pancreatic cancer is the third leading cause of cancer-related deaths, this work for PharmaCyte is important and necessary, and the company has painstakingly endured a process of perfection to land it on the precipice of engaging with the FDA in an opportunity to enter into a clinical trial.  In 2020 alone, an estimated 57,600 Americans will be diagnosed with pancreatic cancer, and approximately 47,050 Americans are expected to die from the disease this year. 

PharmaCyte hopes to better those dismal numbers by using its targeted chemotherapy—Cell-in-a-Box® plus low doses of the anticancer drug ifosfamide—in patients with LAPC who no longer see any benefit after being treated for 4-6 months with one of the two first-line therapies offered to this patient population.  Its stated goal is to make inoperable tumors operable and give these patients a second chance at life.  Needless to say, PharmaCyte is closer than ever to submitting its IND, so the countdown to this momentous milestone for the company’s shareholders should be “officially” underway and is certainly highly anticipated.

To learn more about PharmaCyte’s pancreatic cancer treatment and how it works inside the body to treat locally advanced inoperable pancreatic cancer, watch the company’s documentary video complete with medical animations at: https://www.PharmaCyte.com/Cancer

About PharmaCyte Biotech

PharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.

PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in little to no treatment related side effects.

PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is developing the use of genetically modified liver cells and stem cells, as well beta islet cells, to treat diabetes. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a “bio-artificial pancreas” for purposes of insulin production.

About Stock Market Media Group

Stock Market Media Group is a Content Development IR firm offering a platform for corporate stories to unfold in the media with press releases, research reports, corporate videos, radio-style CEO interviews and feature news articles.

This article was written based upon publicly available information. Stock Market Media Group may, from time to time, include our own opinions about the companies, their business, markets and opportunities in our articles. Any opinions we may offer about any of the companies we write about are solely our own and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any of the securities we write about are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid, and as a starting point for doing additional independent research. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at: www.sec.gov, where you can also find all of PMCB’s filings and disclosures. We also recommend, as a general rule, that before investing in any securities, you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks.  We are not a registered broker, dealer, analyst, or advisor. We hold no investment licenses and may not sell, offer to sell or offer to buy any security. Our publications about PMCB are not a recommendation to buy or sell a security.

Stock Market Media Group and its management may benefit from any increase in the share price of the profiled companies and hold the right to sell the shares bought at any given time including shortly after the release of the company’s profile. Section 17(b) of the 1933 Securities and Exchange Act requires publishers who distribute information about publicly traded securities for compensation, to disclose who paid them, the amount, and the type of payment.  Under the Securities Act of 1933, Section 17(b), Stock Market Media Group discloses that it expects to be remunerated fifteen thousand dollars monthly from September 2019 to September 2020, paid for by a third party via bank wire, to produce content related to PharmaCyte. This article is the opinion of Stock Market Media Group and was written based upon publicly available information and interviews conducted by SMMG.

Stock Market Media Group does not own any shares in PharmaCyte and never accepts compensation in free-trading shares for its marketing services of the company being profiled, however third parties that might have compensated Stock Market Media Group may hold free-trading shares of the company being profiled and could very well be selling, holding or buying shares of the company’s stock at the same time the content is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

If Stock Market Media Group ever accepts compensation in the form of free trading shares of the company being profiled and decides to sell these shares into the public market at any time before, during, or after the release of the company’s profile, our disclaimer will be updated accordingly reflecting the current position of those free trading shares received as compensation for our services.

For more information: www.stockmarketmediagroup.com

Contact:


            

Contact Data